- Home
- ALTS vs ARMP Comparison
ALTS vs ARMP Comparison
Compare ALTS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- ARMP
- Stock Information
- Founded
- ALTS 1976
- ARMP N/A
- Country
- ALTS United States
- ARMP United States
- Employees
- ALTS N/A
- ARMP N/A
- Industry
- ALTS
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALTS
- ARMP Health Care
- Exchange
- ALTS NYSE
- ARMP Nasdaq
- Market Cap
- ALTS 72.7M
- ARMP 80.0M
- IPO Year
- ALTS N/A
- ARMP N/A
- Fundamental
- Price
- ALTS $6.60
- ARMP $2.11
- Analyst Decision
- ALTS
- ARMP Strong Buy
- Analyst Count
- ALTS 0
- ARMP 1
- Target Price
- ALTS N/A
- ARMP $7.00
- AVG Volume (30 Days)
- ALTS 234.3K
- ARMP 8.1K
- Earning Date
- ALTS 04-07-2025
- ARMP 03-20-2025
- Dividend Yield
- ALTS N/A
- ARMP N/A
- EPS Growth
- ALTS N/A
- ARMP N/A
- EPS
- ALTS N/A
- ARMP N/A
- Revenue
- ALTS $7,110,000.00
- ARMP $5,467,000.00
- Revenue This Year
- ALTS N/A
- ARMP $23.87
- Revenue Next Year
- ALTS N/A
- ARMP N/A
- P/E Ratio
- ALTS N/A
- ARMP N/A
- Revenue Growth
- ALTS N/A
- ARMP 34.92
- 52 Week Low
- ALTS $0.94
- ARMP $1.80
- 52 Week High
- ALTS $7.75
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- ALTS 56.27
- ARMP 56.44
- Support Level
- ALTS $4.60
- ARMP $1.85
- Resistance Level
- ALTS $7.75
- ARMP $2.08
- Average True Range (ATR)
- ALTS 0.59
- ARMP 0.12
- MACD
- ALTS 0.05
- ARMP 0.00
- Stochastic Oscillator
- ALTS 56.27
- ARMP 56.67
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.